

LETTER TO THE EDITOR

POLR3A variants in hereditary spastic paraplegia and ataxia

Laurence Gauquelin,^{1,2} Martine Tétreault,^{3,4} Isabelle Thiffault,⁵ Emily Farrow,⁵ Neil Miller,⁵ Byunggil Yoo,⁵ Eric Bareke,^{3,4} Grace Yoon,^{6,7} Oksana Suchowersky,⁸ Nicolas Dupré,⁹ Mark Tarnopolsky,¹⁰ Bernard Brais,^{3,11} Nicole I. Wolf,¹² Jacek Majewski,^{3,4} Guy A. Rouleau,¹¹ Ziv Gan-Or^{3,11} and Geneviève Bernard^{1,2,13,14}

- 1 Department of Neurology and Neurosurgery, Montreal Children's Hospital, McGill University Health Centre, Montreal, Canada
- 2 Department of Pediatrics, Montreal Children's Hospital, McGill University Health Centre, Montreal, Canada
- 3 Department of Human Genetics, McGill University, Montreal, Canada
- 4 Genome Quebec Innovation Centre, Montreal, Canada
- 5 Center for Pediatric Genomic Medicine, Children's Mercy Hospital, Kansas City, Missouri, USA
- 6 Division of Clinical and Metabolic Genetics, The Hospital for Sick Children, University of Toronto, Toronto, Canada
- 7 Division of Neurology, The Hospital for Sick Children, University of Toronto, Toronto, Canada
- 8 Departments of Medicine (Neurology) and Medical Genetics, University of Alberta, Edmonton, Canada
- 9 Neuroscience Division, CHU de Québec - Université Laval and the Department of Medicine, Faculty of Medicine, Laval University, Quebec City, Canada
- 10 Department of Pediatrics and Medicine, McMaster University, Hamilton, Canada
- 11 Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, Canada
- 12 Department of Child Neurology, VU University Medical Center, and Amsterdam Neuroscience, Amsterdam, The Netherlands
- 13 Child Health and Human Development Program, Research Institute of the McGill University Health Centre, Montreal, Canada
- 14 Department of Medical Genetics, Montreal Children's Hospital, McGill University Health Centre, Montreal, Canada

Correspondence to: Dr Geneviève Bernard
 Address: Research Institute of the McGill University Health Centre
 1001 boul Décarie
 EM02224 (Site Glen, Block E)
 CHHD Mail Drop Point #EM03211 (Cubicle C)
 Montreal, QC H4A 3J1, Canada
 E-mail: genevieve.bernard@mcgill.ca

Sir,

We read with great interest the manuscript entitled 'Hypomorphic mutations in *POLR3A* are a frequent cause of sporadic and recessive spastic ataxia', by [Minnerop *et al.* \(2017\)](#). Based on our own clinical expertise on *POLR3A*-related disorders, as well as data from 745 individuals from 492 families with hereditary spastic paraplegia (HSP) and ataxia, we would like to raise one main concern. Based on the recent literature, we believe that the patients described by [Minnerop *et al.*](#) would have been better categorized as having *POLR3A*-related disorders, rather than ataxia or HSP. Moreover, our genetic data suggest that the intronic variant in *POLR3A* (c.1909+22G>A) is not likely to cause HSP and ataxia,

but rather, atypical *POLR3A*-related disorders as previously reported ([La Piana *et al.*, 2016](#)). Ultimately, functional studies looking at the impact of the c.1909+22G>A intronic variant will shed light on its exact role.

The clinical characteristics of *POLR3A*-related disorders have been described as an overlapping phenotype with features of both ataxia and HSP since the earliest descriptions ([Wolf *et al.*, 2005](#); [Timmons *et al.*, 2006](#); [Bernard *et al.*, 2010](#)). Indeed, patients with *POLR3A*-related disorders have prominent cerebellar features, including gait ataxia, intention tremor, dysmetria and saccadic pursuit. Pyramidal features are typically less prominent, and involve more the lower than the upper extremities. We would like to emphasize that peripheral neuropathy is not a feature of

POLR3-related disorders, as nerve conduction studies (NCS) are normal in all cases our group is aware of. Moreover, the pathological findings described on electron microscopy by Timmons *et al.* (2006) are hypothesized to be most likely artefactual, as they have never been replicated. Therefore, we wonder whether the abnormal NCS reported in six patients (Patients F1-5, F1-8, F3-1, F11-1, F12-1 and F19-1) by Minnerop *et al.* (2017) are caused by another aetiology.

Non-neurological features are not obligatory in POLR3-related disorders and include a wide range of dental abnormalities and endocrine manifestations (typically hypogonadotropic hypogonadism, i.e. pituitary dysfunction rather than gonadal dysfunction). Myopia was not mentioned by Minnerop *et al.*, however, it is the most common non-neurological feature. Another frequent non-neurological manifestation in POLR3-related disorders is short stature, which is seen in approximately half of the patients (Wolf *et al.*, 2014). It would have been interesting to know the height of the patients presented by Minnerop *et al.* Regarding the dental abnormalities, the authors reported a frequency of 65% (11 of 17 cases when asked specifically); however, they did not have the information on 9/29 patients, therefore the frequency of this manifestation in their cohort is not clear. In the largest cohort of POLR3-related leukodystrophy patients published thus far, the frequency of dental abnormalities was significantly higher (87%), and the abnormalities could be very subtle (Wolf *et al.*, 2014). Therefore, we believe that it is useful to routinely add questions about dentition and teeth to the review of systems in patients with neurodegenerative disorders, as dental abnormalities are often not spontaneously reported. Interestingly, seven patients in the cohort of Minnerop *et al.* had a detailed dental evaluation (Patients F1-3, F1-5, F1-7, F1-8, F2-1, F3-1 and F14-1) and all of them were found to have mild abnormalities, possibly suggesting a higher frequency than 65%.

In POLR3-related disorders, brain MRI typically shows hypomyelination with better myelination of specific structures (i.e. dentate nucleus, optic radiation, anterolateral nucleus of the thalamus, globus pallidus, corticospinal tracts at the level of the posterior limb of the internal capsule), with or without thinning of the corpus callosum and atrophy of the cerebellum (Steenweg *et al.*, 2010; La Piana *et al.*, 2014; Wolf *et al.*, 2014). Patients with hypomyelination and absence of these other MRI features are unlikely to have mutations in *POLR3A* or *POLR3B* (Cayami *et al.*, 2015). In our opinion, this observation still holds true. Some patients have atypical MRI patterns without hypomyelination, as described by Minnerop *et al.* and as previously reported (La Piana *et al.*, 2016). Of note, however, Minnerop *et al.* reported complete brain MRI results for only 12/29 patients in their study. Therefore, it may be premature to determine that their cohort does not exhibit the typical white matter features of POLR3-related disorders. Furthermore, the MRI images provided (Fig. 4) are incomplete and it is difficult to examine the presence or

absence of certain previously reported MRI characteristics. Figure 4, B1 (from Minnerop *et al.*, 2017) shows mild superior cerebellar vermis atrophy (that should be confirmed on coronal views) and mild thinning of the corpus callosum without hypomyelination. This pattern has already been described by La Piana *et al.* (2016). Regarding the MRI abnormalities involving the superior cerebellar peduncles, we thank the authors for this observation. We went back to our atypical cases published in 2016 and found 4/8 cases with this same finding. We therefore suggest that this MRI characteristic is not mutation-specific as the authors hypothesized, but rather is part of the MRI pattern seen in atypical POLR3-related disorders. Regarding the homozygous c.1771-7C>G variant, it would have been useful to have the complete MRI features of these patients. This mutation seems to be associated with a very different clinical and, we would assume, MRI phenotype, which appears to be similar to what has been previously reported (Azmanov *et al.*, 2016). Finally, we believe that it is extremely important to review the brain MRI of all patients with ataxia and HSP because the presence of white matter abnormalities can be a major clue to the diagnosis and lead to a significant change in classification of the suspected diseases.

In addition to these clinical considerations, our genetic data suggest that the c.1909+22G>A variant (rs191875469) is unlikely to be a major cause of HSP and ataxia. Our group first reported this variant in 2016; however, its pathogenicity could not be fully resolved at the time as not enough material was available to perform the necessary experiments (La Piana *et al.*, 2016). With the work by Minnerop *et al.* (2017), it now appears clear that the c.1909+22G>A variant is indeed pathogenic. However, our genetic data do not support a role for this variant in large cohorts of HSP and ataxia. We examined exome-sequencing data from 745 individuals from 492 families with HSP and ataxia. The average coverage of *POLR3A* across all samples was >100×, with 100% of the nucleotides covered with >10×. Among 257 families with HSP, the c.1909+22G>A variant was identified in three families. However, in none of them it seemed to be disease-related. One large family had an autosomal dominant pattern of inheritance, which did not fit the recessive model of *POLR3A*-related disorders. Furthermore, the c.1909+22G>A variant did not segregate with the eight affected individuals that were sequenced in this family. In two other families with only one patient in each, the two patients were heterozygous carriers of the c.1909+22G>A variant but did not carry any other *POLR3A* mutation. However, we still cannot rule out structural variants or large copy number variations in *POLR3A* that cannot be detected in exome sequencing. In 135 families with ataxia, which included 170 individuals, the c.1909+22G>A variant was not identified at all. The allele frequency of this variant in our index cases was 0.33%, very similar to the control frequencies reported by Minnerop *et al.* (2017) (0.38% and 0.35%).

In conclusion, we would like to reiterate the importance of classifying patients with neurodegenerative disorders by combining fine clinical phenotyping and MRI features, as it can be of great help to target the investigations. Regarding the cohort reported by Minnerop *et al.* (2017), we would first recommend a thorough expert review of the brain MRI of all patients. We would hypothesize that several, if not all cases, would probably be categorized as POLR3-related disorders rather than HSP or ataxia. The genetic evaluation of the potentially non-POLR3-related cases (if any) could be completed by whole exome or genome sequencing to identify another genetic aetiology. We would also suggest looking for large deletions or duplications in patients with a compatible phenotype to find any other disease-causing variant.

Acknowledgements

The authors are grateful to the patients and their families for their participation. We also wish to acknowledge the McGill University and Génome Québec Innovation Centre for use of their high throughput sequencing platform. This work was done as a part of a Canadian collaboration to study HSP (CanHSP).

Funding

This study was supported by grants from the CIHR (201610PJT-377869 and MOP-G2-341146-159133-BRIDG), the Fondation Lueur d'Espoir pour Ayden, the Fondation les Amis d'Elliot and the Réseau de Médecine Génétique Appliquée. This study was funded by CIHR Emerging Team Grant, in collaboration with the Canadian Organization for Rare Disorders (CORD), grant number RN127580 – 260005. G.A.R. holds a Canada Research Chair in Genetics of the Nervous System and the Wilder Penfield Chair in Neurosciences. G.B. has received a Research Scholar Junior 1 award

from the Fonds de Recherche du Québec en Santé (FRQS) (2012–2016) and the New Investigator Salary Award from the Canadian Institutes of Health Research (2017–2022). M.T. has received a post-doctoral fellowship from the CIHR. O.S. is supported by the Toupin Foundation, U of Alberta.

References

- Azmanov DN, Siira SJ, Chamova T, Kaprelyan A, Guergueltcheva V, Shearwood AJ, et al. Transcriptome-wide effects of a POLR3A gene mutation in patients with an unusual phenotype of striatal involvement. *Hum Mol Genet* 2016; 25: 4302–14.
- Bernard G, Thiffault I, Tetreault M, Putorti ML, Bouchard I, Sylvain M, et al. Tremor-ataxia with central hypomyelination (TACH) leukodystrophy maps to chromosome 10q22.3-10q23.31. *Neurogenetics* 2010; 11: 457–64.
- Cayami FK, La Piana R, van Spaendonk RM, Nickel M, Bley A, Guerrero K, et al. POLR3A and POLR3B mutations in unclassified hypomyelination. *Neuropediatrics* 2015; 46: 221–8.
- La Piana R, Cayami FK, Tran LT, Guerrero K, van Spaendonk R, Ounap K, et al. Diffuse hypomyelination is not obligate for POLR3-related disorders. *Neurology* 2016; 86: 1622–6.
- La Piana R, Tonduti D, Gordish Dressman H, Schmidt JL, Murnick J, Brais B, et al. Brain magnetic resonance imaging (MRI) pattern recognition in Pol III-related leukodystrophies. *J Child Neurol* 2014; 29: 214–20.
- Minnerop M, Kurzwelley D, Wagner H, Soehn AS, Reichbauer J, Tao F, et al. Hypomorphic mutations in POLR3A are a frequent cause of sporadic and recessive spastic ataxia. *Brain* 2017; 140: 1561–78.
- Steenweg ME, Vanderver A, Blaser S, Bizzi A, de Koning TJ, Mancini GM, et al. Magnetic resonance imaging pattern recognition in hypomyelinating disorders. *Brain* 2010; 133: 2971–82.
- Timmons M, Tsokos M, Asab MA, Seminara SB, Zirzow GC, Kaneski CR, et al. Peripheral and central hypomyelination with hypogonadotropic hypogonadism and hypodontia. *Neurology* 2006; 67: 2066–9.
- Wolf NI, Harting I, Boltshauser E, Wiegand G, Koch MJ, Schmitt-Mechelke T, et al. Leukoencephalopathy with ataxia, hypodontia, and hypomyelination. *Neurology* 2005; 64: 1461–4.
- Wolf NI, Vanderver A, van Spaendonk RM, Schiffmann R, Brais B, Bugiani M, et al. Clinical spectrum of 4H leukodystrophy caused by POLR3A and POLR3B mutations. *Neurology* 2014; 83: 1898–905.